Immutep Limited Class Action Lawsuit - IMMP
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Immutep class action lawsuit seeks to represent purchasers or acquirers of Immutep Limited (NASDAQ: IMMP) American Depositary Receipts (“ADRs”) between March 24, 2025 and March 12, 2026, inclusive (the “Class Period”). Captioned Dhaenens v. Immutep Limited, No. 26-cv-03705 (S.D.N.Y.), the Immutep class action lawsuit charges Immutep and certain of Immutep’s top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Immutep class action lawsuit, please provide your information in the form on this page. You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Immutep class action lawsuit must be filed with the court no later than July 6, 2026.
CASE ALLEGATIONS: Immutep is a biotechnology company that engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. According to the complaint, Immutep’s TACTI-004 Phase III trial evaluated eftilagimod alfa (efti) in patients with advanced lung cancer.
The Immutep class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants concealed and misrepresented the status and prospects of the TACTI-004 trial based on continuing positive efficacy and safety readouts of efti’s performance in other trials, particularly following positive top-line results from Immutep’s prior TACTI-002 and INSIGHT-003 studies; (ii) defendants announced that the trial was exhibiting “strong operational progress” and the planned interim futility analysis remained “on track for the first quarter of CY2026”; and (iii) Immutep was aware of or was reckless, based on its access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints.
On March 13, 2026, defendants allegedly announced that the Independent Data Monitoring Committee (“IDMC”) for the TACTI-004 Phase III study evaluating efti in patients in first line non-small cell lung cancer recommended discontinuing the trial following a planned interim futility analysis. Defendants further allegedly announced that, “[b]ased on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility.” On this news, the price of Immutep ADRs fell more than 82%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Immutep ADRs during the Class Period to seek appointment as lead plaintiff in the Immutep class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Immutep class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Immutep class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Immutep class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.